Abstract
Background Preclinical and human genetics studies suggest that impaired glucose-dependent insulinotropic polypeptide receptor (GIPR) signalling worsens glycaemic control. The relationship between GIPR signalling and risk of cancers influenced by impaired glucose homeostasis is unclear.
Methods We examined the association of a missense variant in GIPR, rs1800437 (E354Q), shown to impair long-term GIPR signalling and lower circulating GIP concentrations, with risk of 6 cancers influenced by impaired glucose homeostasis. Summary genetic association data on breast, colorectal, endometrial, lung, pancreatic, and renal cancer risk were obtained from GWAS consortia (235,698 cases, 333,932 controls). Replication analyses were performed in the FinnGen consortium (8,401 breast cancer cases, 99,321 controls). Colocalisation was performed to examine robustness of findings to genetic confounding. Finally, we examined the association of E354Q with potential downstream molecular mediators of GIPR signalling to identify possible mechanisms underpinning an effect on cancer risk.
Results Each copy of E354Q was associated with a higher risk of overall breast cancer (OR:1.05,95%CI:1.03-1.06,P=4.23×10−9) and luminal A-like breast cancer (OR:1.05,95%CI:1.03-1.06,P=6.02×10−7). In replication analysis, E354Q was likewise associated with breast cancer risk (OR:1.06,95%CI:1.02-1.08,P=1.09×10−3) and in colocalisation there was a >99.9% posterior probability of circulating GIP concentrations sharing a causal variant with overall and luminal A-like breast cancer in GIPR. E354Q was not associated with risk of the 5 other cancers examined. In mechanistic analysis, this variant was associated with higher postprandial glucose concentrations but diminished insulin secretion and lower testosterone concentrations.
Conclusion Our comprehensive drug target-Mendelian randomization analysis across 6 cancers suggests an adverse effect of the GIPR E354Q variant on overall and luminal A-like breast cancer risk. These findings provide genetic evidence to support further evaluation of the therapeutic potential of GIPR signalling in breast cancer prevention.
Competing Interest Statement
TR has received funding from Amgen and Daiichi-Sankyo to attend educational events unrelated to this work. All other authors declare no potential conflicts of interest.
Funding Statement
GDS, RMM and JY are supported by Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). GDS, RMM, and JY are part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and MC_UU_00011/4) and the University of Bristol. JY is supported by a Cancer Research UK Population Research Postdoctoral Fellowship (C68933/A28534). RMM is also supported by the NIHR Bristol Biomedical Research Centre (BRC-1215-20011) which is funded by the NIHR and is a partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. RMM is a National Institute for Health Research Senior Investigator (NIHR202411). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. TR is supported by a National Institute of Health Research Development and Skills Enhancement Award (NIHR302363). MR is an Academic Foundation Doctor in the Severn Foundation School. EA was funded by the Swedish Research Council (2020-02191). Disclaimer: Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Summary genetic association data for select cancer endpoints were obtained from the public domain: breast cancer (https://bcac.ccge.medschl.cam.ac.uk/bcacdata/), breast cancer in BRCA1/2 mutation carriers (https://cimba.ccge.medschl.cam.ac.uk/projects/), endometrial cancer (https://www.ebi.ac.uk/gwas/), and lung cancer (https://www.ebi.ac.uk/gwas/). Data on pancreatic cancer were obtained via dbGaP release phs000206.v5.p3. Summary genetic association data for colorectal cancer can be accessed by contacting GECCO (kafdem{at}fredhutch.org). Summary genetic association data from the Finngen consortium can be accessed by visiting https://www.finngen.fi/en/access_results. Summary genetic association data from the MAGIC consortium can be obtained by visiting https://magicinvestigators.org/downloads/. Summary genetic association data from the GIANT consortium can be obtained by visiting https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium. Summary genetic association data from the DIAGRAM consortium an be obtained by visiting https://diagram-consortium.org/downloads.html. Summary genetic association data on UK Biobank-derived traits can be accessed via the IEU Open GWAS project (https://gwas.mrcieu.ac.uk/). All other relevant data are within the manuscript and its Supporting Information files.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary genetic association data for select cancer endpoints were obtained from the public domain: breast cancer (https://bcac.ccge.medschl.cam.ac.uk/bcacdata/), breast cancer in BRCA1/2 mutation carriers (https://cimba.ccge.medschl.cam.ac.uk/projects/), endometrial cancer (https://www.ebi.ac.uk/gwas/), and lung cancer (https://www.ebi.ac.uk/gwas/). Data on pancreatic cancer were obtained via dbGaP release phs000206.v5.p3. Summary genetic association data for colorectal cancer can be accessed by contacting GECCO (kafdem{at}fredhutch.org). Summary genetic association data from the Finngen consortium can be accessed by visiting https://www.finngen.fi/en/access_results. Summary genetic association data from the MAGIC consortium can be obtained by visiting https://magicinvestigators.org/downloads/. Summary genetic association data from the GIANT consortium can be obtained by visitinghttps://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium. Summary genetic association data from the DIAGRAM consortium an be obtained by visiting https://diagram-consortium.org/downloads.html. Summary genetic association data on UK Biobank-derived traits can be accessed via the IEU Open GWAS project (https://gwas.mrcieu.ac.uk/). All other relevant data are within the manuscript and its Supporting Information files.